Status:

RECRUITING

Video-oculography and Parkinson's Disease

Lead Sponsor:

Association de Recherche Bibliographique pour les Neurosciences

Collaborating Sponsors:

Centre Hospitalier Princesse Grace

Centre Hospitalier Universitaire de Nice

Conditions:

Parkinson Disease, Idiopathic

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This study aims to study, in patient with Parkinson's disease, mild to moderate stage (according to Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease, Postuma et al., 2015...

Eligibility Criteria

Inclusion

  • \*
  • Male or Female;
  • Clinically defined idiopathic Parkinson's Disease (PD);
  • Brain MRI performed in routine care in the 12 months preceding inclusion;
  • Cerebral DaTSCAN or cerebral PET with F-DOPA, performed as routine care before inclusion (no time limit), confirming presynaptic dopaminergic denervation;
  • Hoehn \& Yahr score: 1 to 3;
  • Normal clinical examination of oculomotricity (slight impairment of smooth pursuit accepted);
  • Neuro-cognitive disorders: absent or minor (according to DSM5);
  • Sufficient written and oral expression in French;
  • Covered by a health insurance system;
  • Written informed consent signed by the patient;
  • Presence of a caregiver.
  • \*

Exclusion

  • Psychiatric comorbidity (except anxiety or mild to moderate depression);
  • Neurological comorbidity, if significant;
  • Brain MRI showing:
  • significant cerebrovascular pathology (Fazekas I admitted),
  • another brain disease, including stroke.
  • Major cognitive impairment;
  • Absolute exclusion criteria and "Red flags" of the 2015 criteria orienting towards another degenerative pathology of the extrapyramidal system:
  • Cerebellar syndrome
  • Vertical oculomotricity disorders on clinical examination
  • Motor symptoms restricted to the lower limbs
  • Bilateral and perfectly symmetrical parkinsonism
  • Early dystonia
  • Clinical profile suggestive of behavioral variant frontotemporal dementia (bvFTD)
  • Progressive aphasia or apraxia
  • Moderate or severe postural instability and / or early falls
  • Early bulbar dysfunction (dysarthria, swallowing disorders)
  • Ventilatory dysfunction (inspiration)
  • Severe dysautonomia
  • DOPA-resistance
  • Neuroleptic treatment or related
  • Normal MIBG myocardial scintigraphy (if performed).

Key Trial Info

Start Date :

July 7 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2032

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT04731246

Start Date

July 7 2021

End Date

January 1 2032

Last Update

October 1 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Centre Mémoire / Centre de Gérontologie Clinique Rainier III / Princess Grace Hospital

Monaco, Monaco, 98000